Alessandro Riva, M.D., joined Ichnos Sciences in April 2019 to lead the company as Chief Executive Officer. He also sits on the company’s Board of Directors. An oncologist/hematologist by training, Alessandro is known for leading global research and development organizations in large pharmaceutical companies and in developing and registering multiple compounds in oncology spanning from cytotoxic agents to targeted therapies and cell therapies. Alessandro previously worked at Gilead Sciences as EVP and Global Head of Oncology Therapeutics and Cell Therapy where he led the acquisition of Kite Pharma. Before Gilead, Alessandro was EVP and Global Head of Oncology Development and Medical Affairs at Novartis Pharmaceuticals. He was President ad interim of Novartis Oncology during the acquisition of GSK Oncology. At the beginning of his career he worked at Farmitialia Carlo Erba, Rhone Poulenc Rorer, and Aventis. He also co-founded the Breast Cancer International Research Group (BIRG), a global nonprofit cooperative group, and Cancer International Research Group (CIRG), a global clinical research organization where he served as CEO for three years. Alessandro is author and co-author of more than 100 papers and abstracts in the field of oncology. He received his bachelor degree in Medicine and Surgery from the University of Milan and a certificate board in oncology/hematology from the same institution.
“Imprinting indelibly Ichnos’ passion and values to advance science and cure diseases.” – Alessandro Riva, M.D., Chief Executive Officer, Ichnos Sciences
Kala Subramanian, Ph.D., oversees the development and implementation of Ichnos Sciences’ operating model and governance, and leads the company’s strategic development. Prior to joining Ichnos, she held senior-level and strategic positions at multiple companies, such as Kite/Gilead, Crispr Therapeutics, Novartis Pharmaceuticals and Millennium Pharmaceuticals. While at Kite Pharma, Kala defined oncology and cell therapy goals across the organization, and led the development of the organization’s 10-year plan. Kala received her Doctor of Philosophy in chemistry from Cornell University and completed a postdoctoral fellowship at Duke University.
“Building Ichnos Sciences into a leading biotech company that is bringing life-changing therapies to patients around the world.” – Kala Subramanian, Ph.D., Chief of Staff and Head of Strategic Development, Ichnos Sciences
Isabel Carmona leads human resources at Ichnos Sciences. She joined Ichnos from Teva Pharmaceuticals where she was a member of Teva’s Global Operations Human Resources leadership team. Isabel has developed her career across the USA and Europe where she held leadership positions in legal, compliance, operational excellence and human resources in multiple industries – Information Technologies, Financial Services and Life Sciences. Isabel earned her juris doctor degree with a specialty in business law from the Universidad de Sevilla.
“Building a completely different kind of biopharmaceutical organization designed to give team members the space needed to find a potential cure.” – Isabel Carmona, Chief Human Resources Officer, Ichnos Sciences
Patrick E. Flanigan III is a finance leader with over 20 years of experience in the biotechnology industry. Patrick joined Ichnos Sciences in December 2019 as Chief Financial Officer after serving as Senior Vice President of Investor Relations & Treasury for Celgene Corporation. Throughout the course of his career, Patrick has overseen capital allocation planning, strategic initiatives, and conducted equity research on the biotechnology sector for various investment banks. He has been involved in both debt and equity issuances. Patrick holds a Bachelor of Arts in Economics and Political Science from Boston College in Massachusetts.
“A pathway toward progress that enables our future patients and the community to share in the success of Ichnos.” – Patrick E. Flanigan III, Chief Financial Officer, Ichnos Sciences
Martin Wilson is an accomplished attorney with more than 15 years of experience in the pharmaceutical industry. Martin joined Ichnos in January 2020 after serving as General Counsel, Chief Compliance Officer, Corporate Secretary and Head of Human Resources of Teligent, Inc. since 2017. Prior to joining Teligent, Martin served as Vice President and Assistant General Counsel for Endo Pharmaceuticals following the acquisition of Par Pharmaceuticals by Endo. Martin was with Par for over 11 years prior to the acquisition by Endo and served in a number of roles, including as Par’s Chief Compliance Officer. Martin received his B.S. from Saint Joseph’s University and a Juris Doctorate from Villanova University School of Law.
“A future where Ichnos Sciences challenges the biotech ‘status quo’ and creates breakthroughs in medicine.” – Martin L. Wilson, General Counsel, Ichnos Sciences
Dr. Gabriela Gruia is an oncologist with 25 years of experience in the pharmaceutical industry. In her current role, Dr. Gruia’s responsibilities include overseeing Regulatory Sciences, Clinical Operations and Outsourcing, Biostatistics, Clinical Pharmacology and Drug Safety. Prior to joining Ichnos Sciences she was Senior Vice President, Head of Regulatory Affairs in Oncology at Novartis. She previously worked as Senior Director, Clinical Research Oncology at Pharmacia and Pfizer where she designed and conducted Phase I through Phase III clinical trials investigating solid tumor treatments in the metastatic and adjuvant settings. Dr. Gruia has extensive experience in global oncology drug development with small molecules, biologics, immunotherapy, and cell and gene therapy. Her experience includes international regulatory development strategy, submissions and approvals of new molecular entities. Dr. Gruia received her doctorate in medicine from Bucharest Medical School in Romania and has a Masters in Breast Pathology and Mammography from René Huguenin/Curie Institute Cancer Center in Paris, France. She received her training in oncology and hematology from René Descartes University in Paris, France.
“Advancing our pipeline to develop new treatment options that enable patients to potentially make a full recovery and live disease-free.” – Gabriela Gruia, M.D., Chief Development Officer, Ichnos Sciences
Neelufar Mozaffarian, M.D., Ph.D., joined Glenmark Pharmaceuticals in 2019 to lead drug development in the therapeutic areas of Autoimmune Disease and Pain, helping to shape the nascent company that would become Ichnos Sciences. Prior to joining Ichnos Sciences, Dr. Mozaffarian led immunology-based clinical development programs at Abbott/AbbVie, Eli Lilly & Co., and Gilead Sciences. She worked on both large and small molecules across all phases of development, from first-in-human to phase 4 post-marketing trials. She is a board-certified Rheumatologist-Immunologist with both clinical and molecular immunology expertise, having received her M.D. and Ph.D. degrees from Albert Einstein College of Medicine in NY, NY followed by postdoctoral training at the University of Washington in Seattle, WA.
“Reshaping the patient treatment experience to enable healthier lives.” – Neelufar Mozaffarian, M.D., Ph.D., Senior Vice President, Global Head, Autoimmune Disease
M. Lamine Mbow, Ph.D., is responsible for the New Biologics Entity (NBE) unit at Ichnos Sciences. Prior to Ichnos Sciences, Lamine held several leadership positions in the U.S. at Boehringer Ingelheim, Genomics Institute of Novartis Research Foundation (GNF), and Novartis Vaccines and Centocor (Janssen), where he led and advanced several molecules to clinical development. Lamine has authored or co-authored more than 50 peer-reviewed publications and is an inventor and co-inventor of several issued patents and patent applications. He holds a Ph.D. in immunology from the University of Neuchatel in Switzerland and conducted his postdoctoral training at the Centers for Disease Control & Prevention and Colorado State University, both in Fort Collins, CO.
“Advancing treatments built on science to help get us closer to a cure.” – M. Lamine Mbow, Ph.D., Head of NBE, Ichnos Sciences
Grace Maguire leads communications and corporate affairs at Ichnos Sciences. With more than 25 years of pharmaceutical industry experience across several therapeutic categories, Grace’s responsibilities have included setting commercial strategy, product launch, brand communications and lifecycle management. Prior to Ichnos Sciences, she worked at Glenmark Pharmaceuticals as Vice President of Commercial for Specialty and Innovative Products, and at Forest Laboratories, Wyeth Pharmaceuticals and Warner Lambert. She began her career as a sales representative for Zeneca Pharmaceuticals in the New York City area. She has her master’s degree in business administration from the Leonard Stern School of Business at New York University and a bachelor’s degree in biology from St. John’s University in New York.
“Working together to pursue the greatest challenges, with the hopes of offering physicians and patients real progress in treating disease.” – Grace Maguire, Head of Communications and Corporate Affairs, Ichnos Sciences
Roberto Giovannini, Ph.D., is responsible for leading CMC development at Ichnos Sciences. Roberto has more than 20 years of combined pharmaceutical and academic experience in the biotech sector with a focus on process development, covering all aspects of process development and scale-up. Previously, Roberto held multiple positions at Glenmark Pharmaceuticals and Boehringer Ingelheim, leading chemistry, manufacturing and control (CMC) development for early- to late-stage development programs. Earlier in his career as a scientist, Roberto was at Bayer HealthCare, where he was in charge of process development for new therapeutics. He has a Ph.D. in purification of proteins from Ecole Polytechnique Fédérale de Lausanne and a master’s degree in chemistry from the University of Geneva.
“Developing first-in-class treatments built on science that will make a positive impact on patients’ lives.” – Roberto Giovannini, Ph.D., Head of CMC Development, Ichnos Sciences
Glenn Saldanha is the Chairman and Managing Director of Glenmark Pharmaceuticals Ltd. He joined in 1998 as Director and took over as Managing Director and CEO in 2001. As Chairman and Managing Director of Glenmark, Glenn oversees all operations of the organization. During his tenure, he transformed Glenmark into a truly global organization with revenues of more than $1 billion and a commercial presence in more than 50 countries. Under his leadership, Glenmark has evolved from a generics business into a research-driven and innovation-led organization. He holds a bachelor’s degree in pharmacy from Mumbai University in India and has a master’s degree in business administration from the Leonard Stern School of Business at New York University. Prior to Glenmark, he worked with Eli Lilly, USA and PricewaterhouseCoopers, USA.
Alessandro Riva, M.D., joined Ichnos Sciences in April 2019 to lead the company as Chief Executive Officer. An oncologist/hematologist by training, Alessandro is known for leading global research and development organizations in large pharmaceutical companies and in developing and registering multiple compounds in oncology spanning from cytotoxic agents to targeted therapies and cell therapies. Alessandro previously worked at Gilead Sciences as EVP and Global Head of Oncology Therapeutics and Cell Therapy where he led the acquisition of Kite Pharma. Before Gilead, Alessandro was EVP and Global Head of Oncology Development and Medical Affairs at Novartis Pharmaceuticals. He was President ad interim of Novartis Oncology during the acquisition of GSK Oncology. At the beginning of his career he worked at Farmitialia Carlo Erba, Rhone Poulenc Rorer, and Aventis. He also co-founded the Breast Cancer International Research Group (BIRG), a global nonprofit cooperative group, and Cancer International Research Group (CIRG), a global clinical research organization where he served as CEO for 3 years. Alessandro is author and co-author of more than 100 papers and abstracts in the field of oncology. He received his bachelor degree in Medicine and Surgery from the University of Milan and a certificate board in oncology/hematology from the same institution.
A senior fellow at FasterCures, a center of the Milken Institute, Bernard Munos advises organizations on being better innovators. Bernard is also the founder of the InnoThink Center for Research in Biomedical Innovation, a consultancy that helps biomedical research organizations become better innovators. Prior to that, he served as an advisor for corporate strategy at Eli Lilly, where he focused on disruptive innovation and the radical redesign of R&D. His research on pharmaceutical innovation has been published in Nature and Science, as well as profiled by Forbes magazine. In 2014, FiercePharma named him one of the 25 most influential people in biopharma. He previously served on the Advisory Council of the National Center for Advancing Translational Sciences (NCATS). Currently, he is a member of the National Academy of Medicine’s Forum on Drug R&D and Translation; the Advisory Board of the journal Science Translational Medicine; a non-executive director of Glenmark Pharmaceuticals; and an advisor to or board member of multiple companies and publicly financed research organizations. Bernard has discussed his research at numerous meetings sponsored by the President’s Cancer Panel, the National Institutes of Health Leadership Forum, the U.S. Food and Drug Administration, the World Health Organization, the Organization for Economic Cooperation and Development, the New York Academy of Sciences, the Brookings Institution, the Kauffman Foundation, the U.S. Patent and Trademark Office, the American Chemical Society, as well as leading universities in the U.S., Europe, and Asia. He also blogs about innovation for Forbes and FastCures. He received his master’s degree in business administration from Stanford University, and holds other graduate degrees from the University of California at Davis, and the Paris Institute of Technology for Life, Food and Environmental Sciences in France.
Dennis Purcell is the original founder of Aisling Capital LLC and currently serves as a senior advisor. Previously, he served as the Senior Managing Partner. Prior to Aisling Capital, Dennis served as Managing Director of the Life Sciences Investment Banking Group at Chase H&Q (formerly Hambrecht & Quist) for more than five years. While at H&Q, he was directly involved with more than 200 completed transactions and supervised more than $10 billion of financing and advisory assignments in the pharmaceutical, biotechnology and medical products industries. During his tenure, BioWorld Today and other industry publications cited H&Q as the leading underwriter of life sciences securities. Prior to joining H&Q, Dennis was a Managing Director in the Healthcare Group at PaineWebber, Inc. Dennis is a frequent commentator on the industry and has been honored in the “Biotech Hall of Fame” by Genetic Engineering News, named to the Biotechnology All-Stars list by Forbes ASAP, honored as one of the top 50 Irish-American businessmen and cited as one of the top 100 contributors to the biotechnology industry. He received his master’s degree in business administration from Harvard Business School and his bachelor’s degree in accounting from the University of Delaware.
V S Mani is the Executive Director & Global Chief Financial Officer of Glenmark Pharmaceuticals Limited. He is responsible for the company’s worldwide finance operations and secretarial function, including global accounting, financial reporting, as well as tax and treasury functions. He is a qualified Chartered Accountant from India, and has more than 25 years of rich industry experience across treasury, taxation (direct, indirect & international), accounting, financial planning and analysis, secretarial, legal, audits (internal & statutory), risk management and investor relations. Prior to joining Glenmark in 2017, he was the President-Finance at the Bhartiya Group. He has also held the position of the Chief Financial Officer at Cipla Ltd. and played a key role in the acquisition of various companies in emerging and mature markets for the organization.
Jayaram Philkana is the President and Global Chief Human Resources Officer at Glenmark Pharmaceuticals Ltd. He is responsible for managing the organization’s diverse global talent, including talent acquisition, performance and rewards, leadership development, employee relations and all other aspects of Human Resources strategies. Prior to joining Glenmark, he was the Global Chief Human Resources Officer at UPL Ltd. In addition, Jayaram previously worked with Cargill for more than 18 years and has held a wide range of leadership roles in the United States and Asia Pacific. Earlier in his career, he worked at PricewaterhouseCoopers, SmithKline Beecham and British American Tobacco. He completed his postgraduate studies in Human Resources and Industrial Relations from XLRI School of Business, Jamshedpur, India.
Marcela Maus, M.D., Ph.D. is currently an Assistant Professor at Harvard Medical School, Director of Cellular Immunotherapy at Massachusetts General Hospital (MGH) Cancer Center, and an Attending Physician in the Bone Marrow Transplant and Cell Therapy division of Oncology at MGH. Dr. Maus is well-known for her work as a translational physician-scientist in the field of immunology, particularly as it relates to T-cell immunotherapies and cell therapies in the treatment of cancer, and holds an undergraduate degree from Massachusetts Institute of Technology (MIT) and graduate degrees (M.D., Ph.D.) from University of Pennsylvania. She is an Associate Member of the Broad Institute of Harvard and MIT, and an Associate Member of the Ragon Institute of MGH, MIT, and Harvard. Dr. Maus trained in internal medicine at University of Pennsylvania and in hematology and medical oncology at Memorial Sloan Kettering, and she is board-certified in these three disciplines. In addition to serving on the Board of Ichnos Sciences, she is a member of the Scientific Advisory Boards at TCR2 Therapeutics, Incysus Therapeutics and MicroMedicine, and is a member of the Clinical Advisory Board at Cellectis.
David Lubner has more than 20 years of finance and executive leadership experience and currently serves as Executive Vice President and Chief Financial Officer (CFO) of Ra Pharma, now part of UCB Pharma (acquired April 2020). Before joining Ra Pharma, David served as Senior Vice President, CFO at Tetraphase Pharmaceuticals, Inc, a biotechnology company focused on the discovery and development of novel antibiotics for the treatment of serious and life-threatening multidrug-resistant (MDR) bacterial infections. He also held CFO roles at PharMetrics Inc. a leading patient-based pharmacy and medical claims data informatics company, and at ProScript, where Velcade® (bortezomib), a therapy widely used for treatment of the blood cancer, multiple myeloma, was discovered. In addition, David serves on the Board of Directors of Dyne Therapeutics and Gemini Therapeutics and previously served on the Board of Directors of Nightstar Therapeutics until its acquisition by Biogen in June 2019. He is a Certified Public Accountant (CPA) in the Commonwealth of Massachusetts and a member of the American Institute of CPAs. David received his bachelor’s degree in Accounting and Business Management from Northeastern University and a master’s degree in Taxation from Bentley University.